Aclaris Therapeutics, Inc. (ACRS)
6.45
+0.14
(+2.22%)
USD |
NASDAQ |
Aug 25, 09:37
Aclaris Therapeutics Price to Book Value : 7.239 for Aug. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 7.082 |
| August 21, 2026 | 7.194 |
| August 20, 2026 | 7.104 |
| August 19, 2026 | 7.228 |
| August 18, 2026 | 7.076 |
| August 17, 2026 | 6.644 |
| August 14, 2026 | 6.487 |
| August 13, 2026 | 6.577 |
| August 12, 2026 | 6.555 |
| August 11, 2026 | 6.644 |
| August 10, 2026 | 6.622 |
| August 07, 2026 | 6.633 |
| August 06, 2026 | 6.835 |
| August 05, 2026 | 7.138 |
| August 04, 2026 | 6.712 |
| August 03, 2026 | 6.207 |
| July 31, 2026 | 5.836 |
| July 30, 2026 | 5.971 |
| July 29, 2026 | 5.746 |
| July 28, 2026 | 5.982 |
| July 27, 2026 | 6.027 |
| July 24, 2026 | 5.870 |
| July 23, 2026 | 6.150 |
| July 22, 2026 | 6.308 |
| July 21, 2026 | 6.386 |
| Date | Value |
|---|---|
| July 20, 2026 | 6.252 |
| July 17, 2026 | 6.375 |
| July 16, 2026 | 6.016 |
| July 15, 2026 | 6.285 |
| July 14, 2026 | 6.094 |
| July 13, 2026 | 6.173 |
| July 10, 2026 | 6.263 |
| July 09, 2026 | 6.409 |
| July 08, 2026 | 6.184 |
| July 07, 2026 | 6.308 |
| July 06, 2026 | 6.162 |
| July 02, 2026 | 6.240 |
| July 01, 2026 | 5.993 |
| June 30, 2026 | 5.937 |
| June 29, 2026 | 4.880 |
| June 26, 2026 | 4.861 |
| June 25, 2026 | 4.773 |
| June 24, 2026 | 4.657 |
| June 23, 2026 | 4.783 |
| June 22, 2026 | 4.705 |
| June 18, 2026 | 4.375 |
| June 17, 2026 | 4.297 |
| June 16, 2026 | 4.219 |
| June 15, 2026 | 4.239 |
| June 12, 2026 | 4.200 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Corcept Therapeutics, Inc. | 19.16 |
| Nektar Therapeutics | 2.865 |
| Xeris Biopharma Holdings, Inc. | -- |
| Crinetics Pharmaceuticals, Inc. | 7.527 |
| Alumis, Inc. | 6.545 |
Price to Book Value Related Metrics
| PS Ratio | 101.40 |
| Price | 6.45 |
| Earnings Yield | -9.07% |
| Market Cap | 901.87M |